A Study of WF 10 IV Solution in Patients With Advanced HIV Disease

Launched by OXO CHEMIE GMBH · Aug 30, 2001

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Concurrent Medication:
• Allowed:
• • Approved drugs at a stabilized dose except those specifically excluded.
• • Aerosolized pentamidine (300 mg) once a month for PCP prophylaxis.
• Patients must have:
• • HIV positivity.
• • Absolute CD4 count \< 200 cells/mm3.
• • Intolerance to or refusal to take AZT, ddI, ddC, or d4T.
• • No active opportunistic infection requiring ongoing therapy.
• • Life expectancy at least 3 months.
• • Exclusion Criteria
• Co-existing Condition:
• Patients with the following symptoms or conditions are excluded:
• • Neoplasm other than basal cell carcinoma of the skin.
• • Clinically significant cardiac disease.
• • Anemia.
• Concurrent Medication:
• Excluded:
• • Cytotoxic chemotherapy.
• • Corticosteroids.
• Patients with the following prior conditions are excluded:
• • History of myocardial infarction or arrhythmias.
• Prior Medication:
• Excluded within 2 weeks prior to study entry:
• • Any antiretroviral agent.
• • Interferon.
• • Systemic therapy with biologic response modifiers, corticosteroids, cytotoxic chemotherapy, or neutropenic or nephrotoxic drugs.
• Excluded within 30 days prior to study entry:
• • Investigational drugs.
• Prior Treatment:
• Excluded within 2 weeks prior to study entry:
• • Radiation therapy. Active drug or alcohol abuse.